Shares of Alpha Cognition Inc. (OTC:ACOGF – Get Free Report) traded down 1.3% on Thursday . The company traded as low as C$0.52 and last traded at C$0.52. 33,504 shares changed hands during trading, a decline of 31% from the average session volume of 48,582 shares. The stock had previously closed at C$0.53.
Alpha Cognition Price Performance
The firm has a market cap of C$61.82 million, a PE ratio of -3.74 and a beta of 2.87. The business has a fifty day moving average price of C$0.54 and a two-hundred day moving average price of C$0.56.
About Alpha Cognition
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
Further Reading
- Five stocks we like better than Alpha Cognition
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- Health Care Stocks Explained: Why You Might Want to Invest
- AbbVie Stock: A Perfect Dip for Investors to Buy
- How to Invest in Biotech Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
